Clinical Trial Update: 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Completed Phase 1 study evaluating safety and initial efficacy of the combination of 3-AP followed by fludarabine in patients with relapsed or refractory acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• 3-AP
• Fludarabine (Fludarabine)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED